Such a delayed disease onset might be attributed to the prostacyclin-dependent activity of the compounds, as prostacyclin was shown to inhibit lung tumor development in PPARγ-dependent mechanism [31] that was also shown to be involved in tumor growth arrest in prostate tumors [32, 33]. This evidence concerns the gene PPARG and neoplasm.